Regarding: Humar et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
Maura Iversen
Part of the Immunology and Infectious Disease Commons
Part of the Immunology and Infectious Disease Commons